The aim of this study was to assess the impact of the route of estrogen administration on the risk of recurrent venous thromboembolism (VTE). A total of 1,023 consecutive post-menopausal women aged 45-75 years with a confirmed first VTE were studied. The researchers found that recurrent VTE occurred in 77 women, and after adjustment for potential confounders there was no significant association between the use of transdermal estrogen and recurrent VTE versus non-users. However, women in the oral estrogen group had an increased risk of recurrent VTE. The findings suggest that transdermal estrogen delivery may be safer when considering risk of VTE.
